Piramal Pharma receives SBTi validation for its GHG commitment

17 Sept 2024

Piramal Pharma receives SBTi validation for its GHG commitment

Piramal Pharma has embarked on its sustainability journey as the Science Based Targets initiative (SBTi) officially validated the company's near-term greenhouse gas (GHG) emission reduction targets. This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,' driving its business strategies and strengthening the company's commitment to making consistent, measurable progress toward a more sustainable future.

Piramal Pharma has committed to reduce absolute scope 1 and 2 GHG emissions 42% by FY2030 from a FY2022 base year. Piramal Pharma has also committed to reduce absolute scope 3 GHG emissions from purchased goods and services, fuel and energy related activities, upstream transportation and distribution and use of sold products 25% within the same timeframe. This makes Piramal Pharma the third global pharmaceutical company in India to receive approval from the SBTi.

Top Blogs

blog-article-image-one

Share Market

Top Small Finance Bank Stocks in India

9 mins read . Oct 30, 2024

blog-article-image-one

Insights

blog-article-image-one

Insights

Long Unwinding Meaning

12 mins read . Oct 28, 2024